SRP167041 Track Settings
 
Homo sapiens Epigenomics [Breast, Plasma]   (Human methylome studies)

This track is part of a parent called 'Human methylome studies'. To show other tracks of this parent, go to the Human methylome studies configuration page.

Maximum display mode:       Reset to defaults   

Select views (help):
CpG reads ▾       CpG methylation ▾       AMR       PMD       HMR      
Select subtracks by views and experiment:
 All views CpG reads  CpG methylation  AMR  PMD  HMR 
experiment
SRX4943649 
SRX4943650 
SRX4943652 
SRX4943654 
SRX4943655 
SRX4943657 
SRX4943658 
SRX4943659 
SRX4943660 
SRX4943661 
SRX4943663 
SRX4943664 
SRX4943665 
SRX4943666 
SRX4943668 
SRX4943669 
SRX4943670 
SRX4943671 
SRX4943672 
SRX4943673 
SRX4943674 
SRX4943675 
SRX4943676 
SRX4943677 
SRX4943679 
SRX4943681 
SRX4943683 
SRX4943686 
SRX4943687 
SRX4943688 
SRX4943689 
SRX4943690 
SRX4943691 
SRX4943692 
SRX4943697 
SRX4943698 
SRX4943699 
SRX4943701 
SRX4943703 
SRX4943705 
SRX4943706 
SRX4943707 
SRX4943709 
SRX4943710 
SRX4943711 
SRX4943712 
SRX4943713 
SRX4943714 
SRX4943715 
SRX4943716 
SRX4943717 
SRX4943718 
SRX4943719 
SRX4943720 
SRX4943721 
SRX4943722 
SRX4943723 
SRX4943724 
SRX4943725 
SRX4943727 
SRX4943728 
SRX4943729 
SRX4943730 
SRX4943733 
SRX4943736 
SRX4943737 
SRX4943738 
SRX4943739 
SRX4943740 
SRX4943741 
SRX4943742 
SRX4943743 
SRX4943744 
SRX4943745 
SRX4943746 
SRX4943747 
SRX4943748 
SRX4943749 
SRX4943750 
SRX4943751 
SRX4943752 
SRX4943753 
SRX4943754 
SRX4943755 
SRX4943756 
SRX4943757 
SRX4943758 
SRX4943759 
SRX4943760 
SRX4943761 
SRX4943762 
SRX4943763 
SRX4943764 
SRX4943766 
SRX4943767 
SRX4943768 
SRX4943772 
SRX4943773 
SRX4943774 
SRX4943775 
SRX4943777 
SRX4943778 
SRX4943779 
SRX4943780 
SRX4943781 
SRX4943782 
SRX4943783 
SRX4943784 
SRX4943785 
SRX4943786 
SRX4943787 
SRX4943788 
SRX4943790 
SRX4943791 
SRX4943793 
SRX4943794 
SRX4943795 
SRX4943796 
SRX4943797 
SRX4943800 
SRX4943802 
SRX4943803 
SRX4943804 
SRX4943810 
SRX4943811 
SRX4943812 
experiment
 All views CpG reads  CpG methylation  AMR  PMD  HMR 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX4943650  HMR  Breast / SRX4943650 (HMR)   schema 
hide
 SRX4943649  CpG methylation  Plasma / SRX4943649 (CpG methylation)   schema 
hide
 SRX4943650  CpG methylation  Breast / SRX4943650 (CpG methylation)   schema 
hide
 SRX4943654  HMR  Breast / SRX4943654 (HMR)   schema 
hide
 SRX4943652  CpG methylation  Breast / SRX4943652 (CpG methylation)   schema 
hide
 SRX4943655  HMR  Plasma / SRX4943655 (HMR)   schema 
hide
 SRX4943654  CpG methylation  Breast / SRX4943654 (CpG methylation)   schema 
hide
 SRX4943658  HMR  Plasma / SRX4943658 (HMR)   schema 
hide
 SRX4943655  CpG methylation  Plasma / SRX4943655 (CpG methylation)   schema 
hide
 SRX4943664  HMR  Plasma / SRX4943664 (HMR)   schema 
hide
 SRX4943657  CpG methylation  Plasma / SRX4943657 (CpG methylation)   schema 
hide
 SRX4943666  HMR  Plasma / SRX4943666 (HMR)   schema 
hide
 SRX4943658  CpG methylation  Plasma / SRX4943658 (CpG methylation)   schema 
hide
 SRX4943668  HMR  Plasma / SRX4943668 (HMR)   schema 
hide
 SRX4943659  CpG methylation  Plasma / SRX4943659 (CpG methylation)   schema 
hide
 SRX4943670  HMR  Plasma / SRX4943670 (HMR)   schema 
hide
 SRX4943660  CpG methylation  Plasma / SRX4943660 (CpG methylation)   schema 
hide
 SRX4943671  HMR  Plasma / SRX4943671 (HMR)   schema 
hide
 SRX4943672  HMR  Breast / SRX4943672 (HMR)   schema 
hide
 SRX4943661  CpG methylation  Plasma / SRX4943661 (CpG methylation)   schema 
hide
 SRX4943663  CpG methylation  Plasma / SRX4943663 (CpG methylation)   schema 
hide
 SRX4943673  HMR  Plasma / SRX4943673 (HMR)   schema 
hide
 SRX4943664  CpG methylation  Plasma / SRX4943664 (CpG methylation)   schema 
hide
 SRX4943675  HMR  Plasma / SRX4943675 (HMR)   schema 
hide
 SRX4943665  CpG methylation  Plasma / SRX4943665 (CpG methylation)   schema 
hide
 SRX4943676  HMR  Plasma / SRX4943676 (HMR)   schema 
hide
 SRX4943666  CpG methylation  Plasma / SRX4943666 (CpG methylation)   schema 
hide
 SRX4943677  HMR  Plasma / SRX4943677 (HMR)   schema 
hide
 SRX4943668  CpG methylation  Plasma / SRX4943668 (CpG methylation)   schema 
hide
 SRX4943679  HMR  Plasma / SRX4943679 (HMR)   schema 
hide
 SRX4943669  CpG methylation  Plasma / SRX4943669 (CpG methylation)   schema 
hide
 SRX4943681  HMR  Plasma / SRX4943681 (HMR)   schema 
hide
 SRX4943683  HMR  Plasma / SRX4943683 (HMR)   schema 
hide
 SRX4943670  CpG methylation  Plasma / SRX4943670 (CpG methylation)   schema 
hide
 SRX4943671  CpG methylation  Plasma / SRX4943671 (CpG methylation)   schema 
hide
 SRX4943687  HMR  Plasma / SRX4943687 (HMR)   schema 
hide
 SRX4943672  CpG methylation  Breast / SRX4943672 (CpG methylation)   schema 
hide
 SRX4943688  HMR  Breast / SRX4943688 (HMR)   schema 
hide
 SRX4943689  HMR  Breast / SRX4943689 (HMR)   schema 
hide
 SRX4943673  CpG methylation  Plasma / SRX4943673 (CpG methylation)   schema 
hide
 SRX4943690  HMR  Breast / SRX4943690 (HMR)   schema 
hide
 SRX4943674  CpG methylation  Plasma / SRX4943674 (CpG methylation)   schema 
hide
 SRX4943691  HMR  Breast / SRX4943691 (HMR)   schema 
hide
 SRX4943675  CpG methylation  Plasma / SRX4943675 (CpG methylation)   schema 
hide
 SRX4943676  CpG methylation  Plasma / SRX4943676 (CpG methylation)   schema 
hide
 SRX4943697  HMR  Plasma / SRX4943697 (HMR)   schema 
hide
 SRX4943677  CpG methylation  Plasma / SRX4943677 (CpG methylation)   schema 
hide
 SRX4943698  HMR  Plasma / SRX4943698 (HMR)   schema 
hide
 SRX4943679  CpG methylation  Plasma / SRX4943679 (CpG methylation)   schema 
hide
 SRX4943699  HMR  Plasma / SRX4943699 (HMR)   schema 
hide
 SRX4943681  CpG methylation  Plasma / SRX4943681 (CpG methylation)   schema 
hide
 SRX4943701  HMR  Plasma / SRX4943701 (HMR)   schema 
hide
 SRX4943683  CpG methylation  Plasma / SRX4943683 (CpG methylation)   schema 
hide
 SRX4943703  HMR  Plasma / SRX4943703 (HMR)   schema 
hide
 SRX4943686  CpG methylation  Plasma / SRX4943686 (CpG methylation)   schema 
hide
 SRX4943706  HMR  Plasma / SRX4943706 (HMR)   schema 
hide
 SRX4943687  CpG methylation  Plasma / SRX4943687 (CpG methylation)   schema 
hide
 SRX4943707  HMR  Plasma / SRX4943707 (HMR)   schema 
hide
 SRX4943688  CpG methylation  Breast / SRX4943688 (CpG methylation)   schema 
hide
 SRX4943712  HMR  Plasma / SRX4943712 (HMR)   schema 
hide
 SRX4943689  CpG methylation  Breast / SRX4943689 (CpG methylation)   schema 
hide
 SRX4943714  HMR  Plasma / SRX4943714 (HMR)   schema 
hide
 SRX4943690  CpG methylation  Breast / SRX4943690 (CpG methylation)   schema 
hide
 SRX4943716  HMR  Plasma / SRX4943716 (HMR)   schema 
hide
 SRX4943691  CpG methylation  Breast / SRX4943691 (CpG methylation)   schema 
hide
 SRX4943717  HMR  Plasma / SRX4943717 (HMR)   schema 
hide
 SRX4943692  CpG methylation  Plasma / SRX4943692 (CpG methylation)   schema 
hide
 SRX4943719  HMR  Plasma / SRX4943719 (HMR)   schema 
hide
 SRX4943697  CpG methylation  Plasma / SRX4943697 (CpG methylation)   schema 
hide
 SRX4943720  HMR  Plasma / SRX4943720 (HMR)   schema 
hide
 SRX4943722  HMR  Plasma / SRX4943722 (HMR)   schema 
hide
 SRX4943698  CpG methylation  Plasma / SRX4943698 (CpG methylation)   schema 
hide
 SRX4943699  CpG methylation  Plasma / SRX4943699 (CpG methylation)   schema 
hide
 SRX4943723  HMR  Plasma / SRX4943723 (HMR)   schema 
hide
 SRX4943701  CpG methylation  Plasma / SRX4943701 (CpG methylation)   schema 
hide
 SRX4943724  HMR  Plasma / SRX4943724 (HMR)   schema 
hide
 SRX4943725  HMR  Plasma / SRX4943725 (HMR)   schema 
hide
 SRX4943703  CpG methylation  Plasma / SRX4943703 (CpG methylation)   schema 
hide
 SRX4943705  CpG methylation  Plasma / SRX4943705 (CpG methylation)   schema 
hide
 SRX4943727  HMR  Plasma / SRX4943727 (HMR)   schema 
hide
 SRX4943706  CpG methylation  Plasma / SRX4943706 (CpG methylation)   schema 
hide
 SRX4943728  HMR  Plasma / SRX4943728 (HMR)   schema 
hide
 SRX4943707  CpG methylation  Plasma / SRX4943707 (CpG methylation)   schema 
hide
 SRX4943730  HMR  Plasma / SRX4943730 (HMR)   schema 
hide
 SRX4943709  CpG methylation  Plasma / SRX4943709 (CpG methylation)   schema 
hide
 SRX4943733  HMR  Plasma / SRX4943733 (HMR)   schema 
hide
 SRX4943710  CpG methylation  Plasma / SRX4943710 (CpG methylation)   schema 
hide
 SRX4943737  HMR  Plasma / SRX4943737 (HMR)   schema 
hide
 SRX4943711  CpG methylation  Plasma / SRX4943711 (CpG methylation)   schema 
hide
 SRX4943738  HMR  Plasma / SRX4943738 (HMR)   schema 
hide
 SRX4943712  CpG methylation  Plasma / SRX4943712 (CpG methylation)   schema 
hide
 SRX4943739  HMR  Plasma / SRX4943739 (HMR)   schema 
hide
 SRX4943713  CpG methylation  Plasma / SRX4943713 (CpG methylation)   schema 
hide
 SRX4943740  HMR  Plasma / SRX4943740 (HMR)   schema 
hide
 SRX4943714  CpG methylation  Plasma / SRX4943714 (CpG methylation)   schema 
hide
 SRX4943742  HMR  Plasma / SRX4943742 (HMR)   schema 
hide
 SRX4943715  CpG methylation  Plasma / SRX4943715 (CpG methylation)   schema 
hide
 SRX4943743  HMR  Plasma / SRX4943743 (HMR)   schema 
hide
 SRX4943716  CpG methylation  Plasma / SRX4943716 (CpG methylation)   schema 
hide
 SRX4943744  HMR  Plasma / SRX4943744 (HMR)   schema 
hide
 SRX4943717  CpG methylation  Plasma / SRX4943717 (CpG methylation)   schema 
hide
 SRX4943745  HMR  Plasma / SRX4943745 (HMR)   schema 
hide
 SRX4943718  CpG methylation  Plasma / SRX4943718 (CpG methylation)   schema 
hide
 SRX4943746  HMR  Plasma / SRX4943746 (HMR)   schema 
hide
 SRX4943719  CpG methylation  Plasma / SRX4943719 (CpG methylation)   schema 
hide
 SRX4943748  HMR  Plasma / SRX4943748 (HMR)   schema 
hide
 SRX4943720  CpG methylation  Plasma / SRX4943720 (CpG methylation)   schema 
hide
 SRX4943749  HMR  Plasma / SRX4943749 (HMR)   schema 
hide
 SRX4943750  HMR  Plasma / SRX4943750 (HMR)   schema 
hide
 SRX4943721  CpG methylation  Plasma / SRX4943721 (CpG methylation)   schema 
hide
 SRX4943722  CpG methylation  Plasma / SRX4943722 (CpG methylation)   schema 
hide
 SRX4943751  HMR  Plasma / SRX4943751 (HMR)   schema 
hide
 SRX4943723  CpG methylation  Plasma / SRX4943723 (CpG methylation)   schema 
hide
 SRX4943752  HMR  Plasma / SRX4943752 (HMR)   schema 
hide
 SRX4943753  HMR  Plasma / SRX4943753 (HMR)   schema 
hide
 SRX4943724  CpG methylation  Plasma / SRX4943724 (CpG methylation)   schema 
hide
 SRX4943725  CpG methylation  Plasma / SRX4943725 (CpG methylation)   schema 
hide
 SRX4943754  HMR  Plasma / SRX4943754 (HMR)   schema 
hide
 SRX4943727  CpG methylation  Plasma / SRX4943727 (CpG methylation)   schema 
hide
 SRX4943755  HMR  Plasma / SRX4943755 (HMR)   schema 
hide
 SRX4943728  CpG methylation  Plasma / SRX4943728 (CpG methylation)   schema 
hide
 SRX4943756  HMR  Plasma / SRX4943756 (HMR)   schema 
hide
 SRX4943729  CpG methylation  Plasma / SRX4943729 (CpG methylation)   schema 
hide
 SRX4943757  HMR  Plasma / SRX4943757 (HMR)   schema 
hide
 SRX4943730  CpG methylation  Plasma / SRX4943730 (CpG methylation)   schema 
hide
 SRX4943761  HMR  Plasma / SRX4943761 (HMR)   schema 
hide
 SRX4943733  CpG methylation  Plasma / SRX4943733 (CpG methylation)   schema 
hide
 SRX4943763  HMR  Plasma / SRX4943763 (HMR)   schema 
hide
 SRX4943736  CpG methylation  Plasma / SRX4943736 (CpG methylation)   schema 
hide
 SRX4943764  HMR  Plasma / SRX4943764 (HMR)   schema 
hide
 SRX4943737  CpG methylation  Plasma / SRX4943737 (CpG methylation)   schema 
hide
 SRX4943766  HMR  Plasma / SRX4943766 (HMR)   schema 
hide
 SRX4943738  CpG methylation  Plasma / SRX4943738 (CpG methylation)   schema 
hide
 SRX4943767  HMR  Plasma / SRX4943767 (HMR)   schema 
hide
 SRX4943739  CpG methylation  Plasma / SRX4943739 (CpG methylation)   schema 
hide
 SRX4943768  HMR  Plasma / SRX4943768 (HMR)   schema 
hide
 SRX4943740  CpG methylation  Plasma / SRX4943740 (CpG methylation)   schema 
hide
 SRX4943772  HMR  Plasma / SRX4943772 (HMR)   schema 
hide
 SRX4943741  CpG methylation  Plasma / SRX4943741 (CpG methylation)   schema 
hide
 SRX4943773  HMR  Plasma / SRX4943773 (HMR)   schema 
hide
 SRX4943742  CpG methylation  Plasma / SRX4943742 (CpG methylation)   schema 
hide
 SRX4943774  HMR  Plasma / SRX4943774 (HMR)   schema 
hide
 SRX4943743  CpG methylation  Plasma / SRX4943743 (CpG methylation)   schema 
hide
 SRX4943775  HMR  Plasma / SRX4943775 (HMR)   schema 
hide
 SRX4943744  CpG methylation  Plasma / SRX4943744 (CpG methylation)   schema 
hide
 SRX4943777  HMR  Plasma / SRX4943777 (HMR)   schema 
hide
 SRX4943778  HMR  Plasma / SRX4943778 (HMR)   schema 
hide
 SRX4943745  CpG methylation  Plasma / SRX4943745 (CpG methylation)   schema 
hide
 SRX4943746  CpG methylation  Plasma / SRX4943746 (CpG methylation)   schema 
hide
 SRX4943779  HMR  Plasma / SRX4943779 (HMR)   schema 
hide
 SRX4943747  CpG methylation  Plasma / SRX4943747 (CpG methylation)   schema 
hide
 SRX4943781  HMR  Plasma / SRX4943781 (HMR)   schema 
hide
 SRX4943782  HMR  Plasma / SRX4943782 (HMR)   schema 
hide
 SRX4943748  CpG methylation  Plasma / SRX4943748 (CpG methylation)   schema 
hide
 SRX4943749  CpG methylation  Plasma / SRX4943749 (CpG methylation)   schema 
hide
 SRX4943783  HMR  Plasma / SRX4943783 (HMR)   schema 
hide
 SRX4943750  CpG methylation  Plasma / SRX4943750 (CpG methylation)   schema 
hide
 SRX4943785  HMR  Plasma / SRX4943785 (HMR)   schema 
hide
 SRX4943751  CpG methylation  Plasma / SRX4943751 (CpG methylation)   schema 
hide
 SRX4943786  HMR  Plasma / SRX4943786 (HMR)   schema 
hide
 SRX4943752  CpG methylation  Plasma / SRX4943752 (CpG methylation)   schema 
hide
 SRX4943787  HMR  Plasma / SRX4943787 (HMR)   schema 
hide
 SRX4943753  CpG methylation  Plasma / SRX4943753 (CpG methylation)   schema 
hide
 SRX4943790  HMR  Plasma / SRX4943790 (HMR)   schema 
hide
 SRX4943754  CpG methylation  Plasma / SRX4943754 (CpG methylation)   schema 
hide
 SRX4943794  HMR  Plasma / SRX4943794 (HMR)   schema 
hide
 SRX4943755  CpG methylation  Plasma / SRX4943755 (CpG methylation)   schema 
hide
 SRX4943797  HMR  Plasma / SRX4943797 (HMR)   schema 
hide
 SRX4943756  CpG methylation  Plasma / SRX4943756 (CpG methylation)   schema 
hide
 SRX4943800  HMR  Plasma / SRX4943800 (HMR)   schema 
hide
 SRX4943757  CpG methylation  Plasma / SRX4943757 (CpG methylation)   schema 
hide
 SRX4943803  HMR  Plasma / SRX4943803 (HMR)   schema 
hide
 SRX4943758  CpG methylation  Plasma / SRX4943758 (CpG methylation)   schema 
hide
 SRX4943804  HMR  Plasma / SRX4943804 (HMR)   schema 
hide
 SRX4943759  CpG methylation  Plasma / SRX4943759 (CpG methylation)   schema 
hide
 SRX4943810  HMR  Plasma / SRX4943810 (HMR)   schema 
hide
 SRX4943760  CpG methylation  Plasma / SRX4943760 (CpG methylation)   schema 
hide
 SRX4943812  HMR  Plasma / SRX4943812 (HMR)   schema 
hide
 SRX4943761  CpG methylation  Plasma / SRX4943761 (CpG methylation)   schema 
hide
 SRX4943762  CpG methylation  Plasma / SRX4943762 (CpG methylation)   schema 
hide
 SRX4943763  CpG methylation  Plasma / SRX4943763 (CpG methylation)   schema 
hide
 SRX4943764  CpG methylation  Plasma / SRX4943764 (CpG methylation)   schema 
hide
 SRX4943766  CpG methylation  Plasma / SRX4943766 (CpG methylation)   schema 
hide
 SRX4943767  CpG methylation  Plasma / SRX4943767 (CpG methylation)   schema 
hide
 SRX4943768  CpG methylation  Plasma / SRX4943768 (CpG methylation)   schema 
hide
 SRX4943772  CpG methylation  Plasma / SRX4943772 (CpG methylation)   schema 
hide
 SRX4943773  CpG methylation  Plasma / SRX4943773 (CpG methylation)   schema 
hide
 SRX4943774  CpG methylation  Plasma / SRX4943774 (CpG methylation)   schema 
hide
 SRX4943775  CpG methylation  Plasma / SRX4943775 (CpG methylation)   schema 
hide
 SRX4943777  CpG methylation  Plasma / SRX4943777 (CpG methylation)   schema 
hide
 SRX4943778  CpG methylation  Plasma / SRX4943778 (CpG methylation)   schema 
hide
 SRX4943779  CpG methylation  Plasma / SRX4943779 (CpG methylation)   schema 
hide
 SRX4943780  CpG methylation  Plasma / SRX4943780 (CpG methylation)   schema 
hide
 SRX4943781  CpG methylation  Plasma / SRX4943781 (CpG methylation)   schema 
hide
 SRX4943782  CpG methylation  Plasma / SRX4943782 (CpG methylation)   schema 
hide
 SRX4943783  CpG methylation  Plasma / SRX4943783 (CpG methylation)   schema 
hide
 SRX4943784  CpG methylation  Plasma / SRX4943784 (CpG methylation)   schema 
hide
 SRX4943785  CpG methylation  Plasma / SRX4943785 (CpG methylation)   schema 
hide
 SRX4943786  CpG methylation  Plasma / SRX4943786 (CpG methylation)   schema 
hide
 SRX4943787  CpG methylation  Plasma / SRX4943787 (CpG methylation)   schema 
hide
 SRX4943788  CpG methylation  Plasma / SRX4943788 (CpG methylation)   schema 
hide
 SRX4943790  CpG methylation  Plasma / SRX4943790 (CpG methylation)   schema 
hide
 SRX4943791  CpG methylation  Plasma / SRX4943791 (CpG methylation)   schema 
hide
 SRX4943793  CpG methylation  Plasma / SRX4943793 (CpG methylation)   schema 
hide
 SRX4943794  CpG methylation  Plasma / SRX4943794 (CpG methylation)   schema 
hide
 SRX4943795  CpG methylation  Plasma / SRX4943795 (CpG methylation)   schema 
hide
 SRX4943796  CpG methylation  Plasma / SRX4943796 (CpG methylation)   schema 
hide
 SRX4943797  CpG methylation  Plasma / SRX4943797 (CpG methylation)   schema 
hide
 SRX4943800  CpG methylation  Plasma / SRX4943800 (CpG methylation)   schema 
hide
 SRX4943802  CpG methylation  Plasma / SRX4943802 (CpG methylation)   schema 
hide
 SRX4943803  CpG methylation  Plasma / SRX4943803 (CpG methylation)   schema 
hide
 SRX4943804  CpG methylation  Plasma / SRX4943804 (CpG methylation)   schema 
hide
 SRX4943810  CpG methylation  Plasma / SRX4943810 (CpG methylation)   schema 
hide
 SRX4943811  CpG methylation  Plasma / SRX4943811 (CpG methylation)   schema 
hide
 SRX4943812  CpG methylation  Plasma / SRX4943812 (CpG methylation)   schema 
    

Study title: Homo sapiens Epigenomics
SRA: SRP167041
GEO: not found
Pubmed: not found

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX4943649 Plasma 0.703 3.6 23718 1679.4 4758 8270.2 453 34758.1 0.977 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ94
SRX4943650 Breast 0.722 8.7 30901 1414.0 34559 2868.2 1191 547487.1 0.984 WGBS of early HER2 subtype breast carcinoma tissue: FD27T
SRX4943652 Breast 0.701 8.9 52346 4621.6 37667 3331.3 1508 383487.8 0.981 WGBS of early Luminal B subtype breast carcinoma tissue: FD17T
SRX4943654 Breast 0.761 9.5 39950 1284.3 19639 3288.8 1641 33912.4 0.986 WGBS of early Luminal B subtype breast pare-carcinoma tissue: FD17N
SRX4943655 Plasma 0.712 3.2 26898 1986.7 4262 8814.4 848 768163.8 0.980 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ88
SRX4943657 Plasma 0.753 3.2 23304 1752.6 1929 17071.0 532 47551.9 0.983 WGBS of advanced HER2 subtype breast cancer ctDNA: TZ85
SRX4943658 Plasma 0.747 3.5 30178 1313.4 2257 14794.6 534 35293.5 0.920 WGBS of early Luminal B her2- subtype breast cancer ctDNA: TZ84
SRX4943659 Plasma 0.656 3.5 37895 4781.7 3526 10010.5 1088 781194.1 0.952 WGBS of early TNBC subtype breast cancer ctDNA: TZ80
SRX4943660 Plasma 0.729 3.8 22322 1743.3 3537 10373.0 630 29506.6 0.976 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ97
SRX4943661 Plasma 0.711 3.4 18463 1785.0 2813 12521.0 543 31393.8 0.973 WGBS of advanced Luminal B her2+ subtype breast cancer ctDNA: TZ95
SRX4943663 Plasma 0.741 3.3 21725 1833.9 2605 12967.2 451 32120.3 0.975 WGBS of healthy human cfDNA: N0034
SRX4943664 Plasma 0.747 2.7 25456 1719.1 1396 22253.2 517 33874.1 0.971 WGBS of healthy human cfDNA: N0028
SRX4943665 Plasma 0.738 3.2 24571 1756.0 2575 13311.5 522 26441.4 0.950 WGBS of healthy human cfDNA: N0027
SRX4943666 Plasma 0.759 2.9 26164 1671.6 1208 25431.3 562 30931.2 0.975 WGBS of healthy human cfDNA: N0026
SRX4943668 Plasma 0.745 4.5 27041 1620.6 4137 8854.1 924 21720.1 0.983 WGBS of healthy human cfDNA: N0033
SRX4943669 Plasma 0.739 3.9 22754 1794.7 2031 16149.6 835 28577.4 0.973 WGBS of healthy human cfDNA: N0032
SRX4943670 Plasma 0.740 3.0 26176 1693.6 1942 16775.1 515 30966.6 0.957 WGBS of healthy human cfDNA: N0031
SRX4943671 Plasma 0.742 3.2 28728 1637.8 1226 25151.1 776 24613.8 0.973 WGBS of healthy human cfDNA: N0029
SRX4943672 Breast 0.777 8.4 37177 1325.2 12352 4107.9 1029 36320.9 0.985 WGBS of early HER2 subtype breast pare-carcinoma tissue: FD27N
SRX4943673 Plasma 0.781 3.7 27652 1566.3 1807 17611.2 740 26551.1 0.973 WGBS of healthy human cfDNA: N0040
SRX4943674 Plasma 0.662 3.7 42047 7050.3 8821 5521.9 1214 531658.7 0.975 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ69
SRX4943675 Plasma 0.744 3.3 28100 1664.7 3264 10508.5 608 33917.5 0.970 WGBS of healthy human cfDNA: N0041
SRX4943676 Plasma 0.750 2.8 28073 1595.6 3048 11099.2 344 43795.7 0.966 WGBS of healthy human cfDNA: N0042
SRX4943677 Plasma 0.791 3.7 27918 1585.8 1556 20180.8 900 28039.1 0.970 WGBS of healthy human cfDNA: N0043
SRX4943679 Plasma 0.776 2.9 26008 1719.3 1416 21661.5 663 41412.3 0.981 WGBS of healthy human cfDNA: N0037
SRX4943681 Plasma 0.771 2.9 26492 1589.6 1953 16247.1 546 32312.0 0.970 WGBS of healthy human cfDNA: N0039
SRX4943683 Plasma 0.772 3.8 29754 1609.1 2179 15122.7 788 29300.8 0.981 WGBS of healthy human cfDNA: N0045
SRX4943686 Plasma 0.750 3.3 24105 1830.8 1897 17151.8 626 44086.5 0.980 WGBS of early Luminal A subtype breast cancer ctDNA: XH23
SRX4943687 Plasma 0.770 3.1 29531 1597.3 1341 22958.8 711 34882.2 0.981 WGBS of early HER2 subtype breast cancer ctDNA: XH21
SRX4943688 Breast 0.744 9.6 33474 1300.4 37221 3018.6 1037 1004643.8 0.983 WGBS of early TNBC subtype breast carcinoma tissue: FD4T
SRX4943689 Breast 0.755 8.8 36656 1255.4 18028 3318.2 1123 22192.0 0.982 WGBS of early TNBC subtype breast pare-carcinoma tissue: FD4N
SRX4943690 Breast 0.712 9.4 41799 2767.5 74160 3399.3 1663 618184.3 0.988 WGBS of early Luminal A subtype breast carcinoma tissue: FD16T
SRX4943691 Breast 0.782 8.3 39113 1296.2 13858 3920.4 1724 26474.8 0.991 WGBS of early Luminal A subtype breast pare-carcinoma tissue: FD16N
SRX4943692 Plasma 0.733 2.8 24201 1783.5 1751 18167.8 520 37580.9 0.976 WGBS of early Luminal B her2+ subtype breast cancer ctDNA: TZ68
SRX4943697 Plasma 0.759 4.3 32970 1539.3 961 31632.2 920 30735.8 0.984 WGBS of advanced Luminal A subtype breast cancer ctDNA: TZ10
SRX4943698 Plasma 0.746 5.0 31688 1483.8 2771 12387.0 881 25405.2 0.982 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ9
SRX4943699 Plasma 0.746 2.8 25452 1814.0 2102 15139.7 525 45867.4 0.978 WGBS of advanced Luminal B her2+ subtype breast cancer ctDNA: TZ12
SRX4943701 Plasma 0.771 4.5 32331 1443.0 1295 23989.7 735 25881.4 0.982 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ15
SRX4943703 Plasma 0.632 4.0 29103 2514.8 27231 3795.1 596 1571973.3 0.975 WGBS of advanced bilateral subtype breast cancer ctDNA: TZ76
SRX4943705 Plasma 0.739 2.3 23544 1926.1 1800 17410.3 431 50151.9 0.976 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ19
SRX4943706 Plasma 0.764 4.3 28266 1511.0 1252 24912.8 888 27894.5 0.982 WGBS of early unknown subtype breast cancer ctDNA: TZ16
SRX4943707 Plasma 0.732 4.0 28967 1587.0 2819 12289.2 745 17034.1 0.979 WGBS of advanced unknown subtype breast cancer ctDNA: TZ17
SRX4943709 Plasma 0.566 5.2 31896 18914.5 14753 4497.4 1986 431428.4 0.981 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ24
SRX4943710 Plasma 0.682 4.9 23743 2100.4 13456 4655.5 1526 162350.9 0.986 WGBS of advanced unknown subtype breast cancer ctDNA: TZ20
SRX4943711 Plasma 0.733 3.6 24139 1768.6 2577 13192.9 655 29842.6 0.976 WGBS of early Luminal B her2+ subtype breast cancer ctDNA: TZ21
SRX4943712 Plasma 0.605 5.3 27355 1977.0 9187 5380.2 618 1793549.4 0.982 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ25
SRX4943713 Plasma 0.702 4.7 24994 1730.4 12877 5070.5 1291 582744.8 0.984 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ27
SRX4943714 Plasma 0.742 2.3 25140 1690.2 491 58874.8 619 37105.4 0.978 WGBS of early unknown subtype breast cancer ctDNA: TZ78
SRX4943715 Plasma 0.741 3.0 24577 1735.0 2646 12739.1 488 50481.0 0.975 WGBS of advanced Luminal B her2+ subtype breast cancer ctDNA: TZ63
SRX4943716 Plasma 0.745 5.1 26782 1498.6 5941 6763.5 820 22473.2 0.983 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ38
SRX4943717 Plasma 0.741 5.4 31986 1524.4 5481 7333.5 819 25676.4 0.981 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ37
SRX4943718 Plasma 0.678 4.3 22956 1758.1 14463 4671.8 698 26472.4 0.971 WGBS of advanced Luminal A subtype breast cancer ctDNA: TZ36
SRX4943719 Plasma 0.731 4.8 25523 1702.9 4834 8089.8 755 18413.7 0.983 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ34
SRX4943720 Plasma 0.717 5.1 25669 1730.5 4834 8091.4 902 28969.3 0.985 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ33
SRX4943721 Plasma 0.519 3.3 15640 31548.9 7773 5665.7 1743 648126.1 0.972 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ32
SRX4943722 Plasma 0.722 3.8 25995 1785.3 2835 12081.6 814 50002.3 0.962 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ31
SRX4943723 Plasma 0.734 4.2 30206 1622.2 1690 19524.5 844 33587.7 0.981 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ30
SRX4943724 Plasma 0.739 4.8 33841 1463.5 5027 8140.1 989 40459.6 0.986 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ29
SRX4943725 Plasma 0.721 5.8 33363 1438.0 3859 9333.9 1154 16403.3 0.984 WGBS of early TNBC subtype breast cancer ctDNA: TZ28
SRX4943727 Plasma 0.730 3.6 29393 1632.1 2171 15077.7 793 29508.7 0.977 WGBS of early Luminal A subtype breast cancer ctDNA: TZ52
SRX4943728 Plasma 0.708 2.9 28254 1760.4 2908 11920.7 443 46257.5 0.958 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ51
SRX4943729 Plasma 0.620 3.1 40122 5224.5 2730 12525.9 963 831701.8 0.984 WGBS of early TNBC subtype breast cancer ctDNA: TZ71
SRX4943730 Plasma 0.758 3.3 28827 1561.2 1644 19391.3 726 25505.3 0.977 WGBS of early HER2 subtype breast cancer ctDNA: TZ54
SRX4943733 Plasma 0.779 4.0 32861 1519.1 1900 16717.7 848 33153.5 0.982 WGBS of early Luminal A subtype breast cancer ctDNA: XH9
SRX4943736 Plasma 0.767 3.7 24135 1572.1 1236 25083.6 601 30946.7 0.978 WGBS of early Luminal A subtype breast cancer ctDNA: XH12
SRX4943737 Plasma 0.784 3.7 31418 1624.5 1617 19355.7 855 32580.6 0.981 WGBS of early Luminal A subtype breast cancer ctDNA: XH4
SRX4943738 Plasma 0.785 4.2 31251 1579.2 1951 16393.4 751 34475.7 0.978 WGBS of early HER2 subtype breast cancer ctDNA: XH5
SRX4943739 Plasma 0.793 3.7 32765 1510.2 1688 18527.5 714 34454.2 0.977 WGBS of early HER2 subtype breast cancer ctDNA: XH6
SRX4943740 Plasma 0.787 3.4 26642 1591.8 746 39879.5 644 30282.3 0.981 WGBS of early Luminal A subtype breast cancer ctDNA: XH8
SRX4943741 Plasma 0.720 3.2 23883 1857.8 2764 12189.0 471 35695.7 0.971 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ49
SRX4943742 Plasma 0.744 3.1 30575 1652.3 1411 21966.6 655 25523.1 0.979 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ50
SRX4943743 Plasma 0.740 4.1 27098 1684.7 5602 7162.4 625 31375.9 0.980 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ75
SRX4943744 Plasma 0.779 3.2 25430 1645.0 1464 21568.0 541 33134.3 0.975 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ145
SRX4943745 Plasma 0.732 4.1 26433 1580.7 4978 7612.3 654 61509.2 0.966 WGBS of advanced HER2 subtype breast cancer ctDNA: TZ146
SRX4943746 Plasma 0.750 4.0 27098 1656.5 1972 16507.3 726 26030.5 0.964 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ143
SRX4943747 Plasma 0.742 4.1 24677 1742.7 3994 9115.7 645 29216.3 0.940 WGBS of early Luminal B her2- subtype breast cancer ctDNA: TZ144
SRX4943748 Plasma 0.764 2.8 25536 1726.1 1727 18523.4 636 35906.7 0.962 WGBS of early Luminal B her2- subtype breast cancer ctDNA: TZ137
SRX4943749 Plasma 0.744 3.8 30830 1617.3 1905 17089.2 791 25412.1 0.978 WGBS of early Luminal B her2- subtype breast cancer ctDNA: TZ142
SRX4943750 Plasma 0.756 3.6 27006 1604.5 1992 16237.7 616 28298.9 0.967 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ135
SRX4943751 Plasma 0.770 3.6 26739 1582.5 979 31121.1 721 33097.4 0.980 WGBS of early Luminal B her2+ subtype breast cancer ctDNA: TZ136
SRX4943752 Plasma 0.725 4.4 28623 1722.8 4771 8005.6 1742 100610.0 0.979 WGBS of advanced Luminal A subtype breast cancer ctDNA: TZ132
SRX4943753 Plasma 0.761 3.4 27238 1679.2 1432 21831.4 652 27145.4 0.949 WGBS of advanced Luminal B her2+ subtype breast cancer ctDNA: TZ134
SRX4943754 Plasma 0.700 3.0 28855 2337.0 8138 5608.8 671 1308858.9 0.978 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ43
SRX4943755 Plasma 0.783 3.9 31023 1527.2 1984 16106.1 781 31392.4 0.978 WGBS of early Luminal B her2+ subtype breast cancer ctDNA: XH2
SRX4943756 Plasma 0.775 3.7 29313 1583.4 1436 21797.0 766 34509.5 0.974 WGBS of early HER2 subtype breast cancer ctDNA: XH1
SRX4943757 Plasma 0.736 3.6 27865 1719.4 5107 7187.9 621 35081.6 0.973 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ153
SRX4943758 Plasma 0.760 3.2 21885 1684.1 4703 7917.6 632 102494.4 0.982 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ152
SRX4943759 Plasma 0.789 3.6 23827 1625.2 1254 24622.2 765 30528.9 0.982 WGBS of early HER2 subtype breast cancer ctDNA: TZ151
SRX4943760 Plasma 0.762 3.8 24910 1717.8 2313 14228.0 755 36879.6 0.973 WGBS of early Luminal B her2+ subtype breast cancer ctDNA: TZ148
SRX4943761 Plasma 0.753 3.6 31639 1586.3 1480 21077.1 704 28989.5 0.981 WGBS of advanced HER2 subtype breast cancer ctDNA: TZ160
SRX4943762 Plasma 0.676 3.2 36601 8016.1 11390 4576.6 1128 578674.4 0.979 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ158
SRX4943763 Plasma 0.731 3.5 26773 1900.3 3748 9502.4 1189 212918.5 0.982 WGBS of advanced Luminal B her2+ subtype breast cancer ctDNA: TZ155
SRX4943764 Plasma 0.786 3.8 30208 1594.2 1915 16530.8 802 27111.5 0.959 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ154
SRX4943766 Plasma 0.716 3.1 25939 1796.9 1922 16627.9 410 38252.6 0.975 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ57
SRX4943767 Plasma 0.739 3.6 25488 1659.0 4385 8601.9 419 35157.7 0.980 WGBS of early Luminal A subtype breast cancer ctDNA: TZ61
SRX4943768 Plasma 0.735 3.5 28355 1689.4 3343 10376.7 552 30166.6 0.973 WGBS of advanced Luminal B her2+ subtype breast cancer ctDNA: TZ59
SRX4943772 Plasma 0.730 4.4 35691 1550.1 3162 10867.9 1044 22656.3 0.975 WGBS of early Luminal B her2- subtype breast cancer ctDNA: TZ53
SRX4943773 Plasma 0.758 4.6 29282 1620.4 3710 9456.8 718 31907.8 0.981 WGBS of early Luminal B her2- subtype breast cancer ctDNA: TZ127
SRX4943774 Plasma 0.781 5.9 35394 1434.7 6346 6166.5 999 28583.6 0.979 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ125
SRX4943775 Plasma 0.767 3.5 25443 1642.0 2295 14294.6 607 32018.4 0.966 WGBS of early HER2 subtype breast cancer ctDNA: TZ129
SRX4943777 Plasma 0.739 3.5 30040 1625.1 1944 16846.5 703 28207.3 0.973 WGBS of early Luminal B her2- subtype breast cancer ctDNA: TZ116
SRX4943778 Plasma 0.756 2.7 26175 1722.6 1986 15893.4 330 40477.4 0.967 WGBS of advanced Luminal B her2+ subtype breast cancer ctDNA: TZ114
SRX4943779 Plasma 0.771 3.3 32077 1568.0 1161 26413.3 569 35111.3 0.976 WGBS of early HER2 subtype breast cancer ctDNA: TZ121
SRX4943780 Plasma 0.748 2.7 24610 1807.6 1556 20111.3 403 48571.6 0.976 WGBS of advanced Luminal A subtype breast cancer ctDNA: TZ120
SRX4943781 Plasma 0.758 4.5 31061 1514.5 2500 13474.9 849 19562.4 0.982 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ39
SRX4943782 Plasma 0.766 4.1 30901 1499.9 1286 24099.0 775 20605.2 0.979 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ40
SRX4943783 Plasma 0.740 4.2 26700 1603.0 1354 23034.9 655 23284.8 0.980 WGBS of early unknown subtype breast cancer ctDNA: TZ41
SRX4943784 Plasma 0.729 2.1 24255 1930.6 1523 19737.3 378 90075.9 0.977 WGBS of advanced Luminal A subtype breast cancer ctDNA: TZ112
SRX4943785 Plasma 0.728 2.7 27964 1723.0 1764 18073.3 602 28255.2 0.972 WGBS of early Luminal B her2- subtype breast cancer ctDNA: TZ113
SRX4943786 Plasma 0.717 3.4 25038 1877.9 2618 12870.5 741 52400.5 0.974 WGBS of advanced Luminal B her2+ subtype breast cancer ctDNA: TZ48
SRX4943787 Plasma 0.760 3.0 25922 1772.5 1282 23985.9 503 31423.4 0.981 WGBS of advanced TNBC subtype breast cancer ctDNA: TZ42
SRX4943788 Plasma 0.736 3.2 20448 1885.9 3161 11217.5 510 31567.9 0.967 WGBS of early TNBC subtype breast cancer ctDNA: TZ66
SRX4943790 Plasma 0.640 4.2 30016 2669.2 33884 3521.4 687 1408610.6 0.979 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ64
SRX4943791 Plasma 0.639 2.4 23322 2314.2 2629 12361.6 251 30807.8 0.969 WGBS of advanced unknown subtype breast cancer ctDNA: TZ65
SRX4943793 Plasma 0.737 2.3 22807 1891.1 1453 21166.5 457 41275.5 0.978 WGBS of early TNBC subtype breast cancer ctDNA: TZ103
SRX4943794 Plasma 0.750 3.5 25137 1534.6 2235 14981.5 513 28131.2 0.974 WGBS of advanced HER2 subtype breast cancer ctDNA: TZ105
SRX4943795 Plasma 0.749 4.1 21743 1602.7 3958 9435.9 501 28124.7 0.968 WGBS of early Luminal A subtype breast cancer ctDNA: TZ106
SRX4943796 Plasma 0.650 3.5 40223 5932.6 6339 6968.8 979 741554.6 0.972 WGBS of advanced Luminal B her2+ subtype breast cancer ctDNA: TZ107
SRX4943797 Plasma 0.747 3.2 29620 1585.8 3431 10120.0 597 31947.1 0.981 WGBS of early TNBC subtype breast cancer ctDNA: TZ108
SRX4943800 Plasma 0.765 4.1 25616 1654.3 2779 12373.5 523 31655.4 0.980 WGBS of advanced Luminal B her2- subtype breast cancer ctDNA: TZ46
SRX4943802 Plasma 0.751 3.8 23913 1588.5 1717 18829.0 605 29280.4 0.964 WGBS of healthy human cfDNA: N0024
SRX4943803 Plasma 0.755 3.7 27883 1603.1 839 35538.9 750 25316.4 0.992 WGBS of healthy human cfDNA: N0021
SRX4943804 Plasma 0.768 3.6 34519 1423.3 976 30989.1 745 29420.0 0.993 WGBS of healthy human cfDNA: N0022
SRX4943810 Plasma 0.758 3.4 28126 1656.6 1319 23359.9 681 26861.0 0.980 WGBS of healthy human cfDNA: N0014
SRX4943811 Plasma 0.759 3.1 24640 1760.1 788 38180.9 778 36710.1 0.992 WGBS of healthy human cfDNA: N0011
SRX4943812 Plasma 0.753 4.0 32752 1507.0 1133 27136.4 810 21414.0 0.991 WGBS of healthy human cfDNA: N0012

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.